New Zealand - English - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - vincristine sulfate 1 mg/ml (expressed on anhydrous basis);   - solution for injection - 1 mg/ml - active: vincristine sulfate 1 mg/ml (expressed on anhydrous basis)   excipient: acetic acid mannitol methyl hydroxybenzoate propyl hydroxybenzoate sodium acetate trihydrate water for injection

New Zealand - English - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - vincristine sulfate 1 mg/ml;   - solution for injection - 1 mg/ml - active: vincristine sulfate 1 mg/ml  

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer (perth) pty ltd - vincristine sulfate, quantity: 1 mg/ml - injection, solution - excipient ingredients: mannitol; sulfuric acid; water for injections; sodium hydroxide - vincristine is effective in hodgkins disease and other lymphomas. in hodgkins disease it is effective for the advanced stages (iii and iv) when used in the mopp regime (mechlorethamine, oncovin, prednisone, procarbazine). in non-hodgkins lymphomas, vincristine is an important agent, particularly when used with cyclophosphamide, bleomycin, doxorubicin and prednisone. vincristine is also effective in lymphocytic leukemia. beneficial responses have been reported in patients with a variety of other neoplasms, particularly wilms tumour, neuroblastoma, brain tumours, rhabdomyosarcoma and carcinomas of the breast, bladder, and the female and male reproductive systems.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer (perth) pty ltd - vincristine sulfate, quantity: 1 mg/ml - injection, solution - excipient ingredients: mannitol; sodium hydroxide; sulfuric acid; water for injections - vincristine is effective in hodgkins disease and other lymphomas. in hodgkins disease it is effective for the advanced stages (iii and iv) when used in the mopp regime (mechlorethamine, oncovin, prednisone, procarbazine). in non-hodgkins lymphomas, vincristine is an important agent, particularly when used with cyclophosphamide, bleomycin, doxorubicin and prednisone. vincristine is also effective in lymphocytic leukemia. beneficial responses have been reported in patients with a variety of other neoplasms, particularly wilms tumour, neuroblastoma, brain tumours, rhabdomyosarcoma and carcinomas of the breast, bladder, and the female and male reproductive systems.

Ireland - English - HPRA (Health Products Regulatory Authority)

eli lilly and company limited - vincristine sulfate - solution for injection - 1 mg/ml

Ireland - English - HPRA (Health Products Regulatory Authority)

eli lilly and company limited - vincristine sulfate - solution for injection - 1 mg/ml

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - vincristine sulfate, quantity: 1 mg - injection, powder for - excipient ingredients: lactose monohydrate; water for injections - oncovin is indicated in acute leukaemia. it has also been shown to be useful in combination with other oncolytic agents in hodgkin's disease, non-hodgkin's malignant lymphomas (lymphocytic, mixed-cell, histiocytic, undifferentiated, nodular, and diffuse types), rhabdomyosarcoma, neuroblastoma, wilms' tumour, osteogenic sarcoma, mycosis fungoides, ewing's sarcoma, carcinoma of the uterine cervix, breast cancer, malignant melanoma, oat-cell carcinoma of the lung, and gynaecologic tumours of childhood. patients with true idiopathic thrombocytopenic purpura resistant to the usual treatment may respond to oncovin. current practices of cancer chemotherapy involve the simultaneous use of several agents. for enhanced therapeutic effect without additive toxicity, agents with different dose-limiting clinical toxicities and different mechanisms of action are generally selected. it is rarely possible to achieve equally good results with single-agent treatment. thus oncovin is often chosen as part of polychemotherapy be

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - vincristine sulfate, quantity: 1 mg - injection, powder for - excipient ingredients: lactose monohydrate - oncovin is indicated in acute leukaemia. it has also been shown to be useful in combination with other oncolytic agents in hodgkin's disease, non-hodgkin's malignant lymphomas(lymphocytic, mixed-cell, histiocytic, undifferentiated, nodular, and diffuse types), rhabdomyosarcoma, neuroblastoma, wilms' tumour, osteogenic sarcoma, mycosis fungoides, ewing's sarcoma, carcinoma of the uterine cervix, breast cancer, malignant melanoma, oat-cell carcinoma of the lung, and gynaecologic tumours of childhood. patients with true idiopathic thrombocytopenic purpura resistant to the usual treatment may respond to oncovin. current practices of cancer chemotherapy involve the simultaneous use of several agents. for enhanced therapeutic effect without additive toxicity, agents with different dose-limiting clinical toxicities and different mechanisms of action are generally selected. it is rarely possible to achieve equally good results with single-agent treatment. thus oncovin is often chosen as part of polychemotherapy becau

Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - filgrastim, quantity: 600 microgram/ml - injection, solution - excipient ingredients: glacial acetic acid; polysorbate 80; sodium hydroxide; sorbitol; water for injections - to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs in doses not usually requiring bone marrow transplantation. to reduce the duration of neutropenia and clinical sequelae in patients undergoing induction and consolidation chemotherapy for acute myeloid leukaemia. for the mobilisation of autologous peripheral blood progenitor cells alone, or following myelosuppressive chemotherapy, in order to accelerate neutrophil and platelet recovery by infusion of such cells after myeloablative or myelosuppressive therapy in patients with nonmyeloid malignancies. for the mobilisation of peripheral blood progenitor cells, in normal volunteers, for use in allogeneic peripheral blood progenitor cell transplantation. in patients receiving myeloablative chemotherapy, to reduce the duration of neutropenia and clinical sequelae following autologous or allogeneic bone marrow transplantation. for chronic administration to

Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - filgrastim, quantity: 600 microgram/ml - injection, solution - excipient ingredients: glacial acetic acid; polysorbate 80; sodium hydroxide; sorbitol; water for injections - to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs in doses not usually requiring bone marrow transplantation. to reduce the duration of neutropenia and clinical sequelae in patients undergoing induction and consolidation chemotherapy for acute myeloid leukaemia. for the mobilisation of autologous peripheral blood progenitor cells alone, or following myelosuppressive chemotherapy, in order to accelerate neutrophil and platelet recovery by infusion of such cells after myeloablative or myelosuppressive therapy in patients with nonmyeloid malignancies. for the mobilisation of peripheral blood progenitor cells, in normal volunteers, for use in allogeneic peripheral blood progenitor cell transplantation. in patients receiving myeloablative chemotherapy, to reduce the duration of neutropenia and clinical sequelae following autologous or allogeneic bone marrow transplantation. for chronic administration to